



BCIN Centro Internacional de Negocios de Badalona  
C/ Marcus Porcius, 1, Polígono Les Guixeres. CP 08915.Badalona, Barcelona



By car: (free parking with 250 places)

- C-31, exit 5 (Badalona Nord Mollet B500) and follow the signs.  
- B-20, exit 22 from Barcelona (Badalona Est Mollet-Tiana) or exit 23 from Mataró (Badalona Est Mollet-Tiana) and follow the signs.

By bus: - Tusgsal B3 bus stop "Mecànica-Les Guixeres", Tusgsal B25 or B4 bus stop "Avda. Pomar".

By subway:- Line 2 (purple), stop Pompeu Fabra. Combine with buses B3, B4 or B25.

By train: - Renfe Mataró/Maçanet. Combine with buses B3, B4 or B25.



TECHNICAL SECRETARIAT:  
Vanessa Díaz Isidoro  
jornadasurobdn@outlook.es  
615 25 34 14

#### FREE REGISTRATION

To formalize the registration it is necessary to send the following information to the technical secretariat:  
Name / Surname / Address / City / Province / Telephone / Mail / Specialty / Work Center

Gold:



Silver:



Bronze:



# 5<sup>th</sup> Translational Research Meeting on Urological Tumors

## FROM THE BENCH TO THE BED

1<sup>st</sup> and 2<sup>nd</sup> December 2022



#### DIRECTORS

Dr. Albert Font Pous - Institut Català d'Oncologia (ICO). Badalona  
Dr. Vicenç Ruiz de Porras - Institut de Recerca Germans Trias i Pujol (IGTP). Badalona

Organiza:



Con el aval científico de:

## PROGRAMA

### DAY 1 – 1<sup>st</sup> DECEMBER 2022

#### 09:00 – 09:10 CONFERENCE OPENING AND WELCOME

Dr. Ramón Salazar. Director General. Institut Català d'Oncologia.

#### SESSION 1. MECHANISMS OF THERAPY RESISTANCE AND PREDICTIVE BIOMARKERS IN METASTATIC PROSTATE CANCER

Chairs: Dr. David Olmos – Hospital 12 Octubre, Madrid | Dr. Begoña Mellado – Hospital Clínic, Barcelona

#### 09:10–09:30 Treatment strategies for metastatic prostate cancer: From “All-Comers” to “Personalized” approach.

Dr. David Lorente – Hospital Universitario Castellón, Castellón.

#### 09:30–09:50 Predictive genomic biomarkers of benefit of hormonal therapy versus chemotherapy benefit in metastatic castration-resistant prostate cancer.

Dr. David Olmos – Hospital 12 de Octubre, Madrid.

#### 09:50–10:10 Molecular characterization of aggressive variants of prostate cancer: Potential clinical implications.

Dr. Begoña Mellado – Hospital Clínic, Barcelona.

#### 10:10–10:30 Analysis of blood-based liquid biopsies as a tool for clinical decision-making in prostate cancer.

Dr. Enrique González - Billalabeitia – Hospital 12 de Octubre, Madrid.

10:30–11:00 Discussion

#### 11:00–11:30 COFFEE-BREAK

#### SESSION 2. NEW INSIGHTS INTO CANCER METABOLISM: THERAPEUTIC IMPLICATIONS

Chairs: Dr. Manel Puig – IGTP-Hospital Germans Trias i Pujol, Badalona | Dr. Mireia Jordà – IGTP, Badalona

#### 11:30–11:50 What is the link between obesity and cancer?

Dr. Manel Puig – IGTP-HUGTIP, Badalona.

#### 11:50–12:10 Metastatic-initiating cells and lipid metabolism.

Dr. Gloria Pascual– Institut de Recerca Biomèdica (IRB), Barcelona.

#### 12:10–12:30 Lipid metabolism and epigenetics crosstalk in prostate cancer.

Dr. Mireia Jordà – IGTP, Badalona.

#### 12:30–12:50 Metabolic reprogramming as an emerging mechanism of resistance to therapy in prostate cancer.

Dr. Lisa M. Butler – South Australian Health and Medical Research Institute, University of Adelaide, Medical School and Freemasons Foundation Centre for Men's Health, Adelaide. Australia.

12:50–13:20 Discussion

#### 13:20–14:30 LUNCH

#### SESSION 3. IMMUNOTHERAPY IN UROLOGICAL TUMORS: STATE-OF-THE-ART AND FUTURE PERSPECTIVE

Chairs: Dr. Jesús Paramio – CIEMAT, Madrid | Dr. Alejo Rodríguez-Vida – Hospital del Mar – IMIM Research Institute, Barcelona

#### 14:30–15:10 Understanding the tumor microenvironment in urological tumors:

- **14:30 – 14:50 Tumor microenvironment in prostate cancer: Toward identification of novel molecular biomarkers for therapy development**

Dr. Josep M<sup>a</sup> Piulats – Institut Català d'Oncologia, L'Hospitalet del Llobregat.

- **14:50 – 15:10 Promalignant effects of antiangiogenics in the renal tumor microenvironment**

Dr. Oriol Casanovas – Institut Català d'Oncologia – IDIBELL, L'Hospitalet del Llobregat.

#### 15:10-15:30 Immunotherapy in bladder cancer: Evolution in revolution or revolution in evolution

Dr. Jesús Paramio – CIEMAT, Madrid.

#### 15:30–15:50 Immunotherapy-based combination strategies for advanced urothelial cancer: A long quest.

Dr. Alejo Rodríguez-Vida– Hospital del Mar-IMIM Research Institute, Barcelona.

#### 15:50–16:10 Radiomics-based prediction model for outcomes of PD-1/PD-L1 immunotherapy in metastatic urothelial carcinoma.

Dr. Raquel Pérez-López – Hospital Vall d'Hebron, Barcelona.

16:10–16:30 Discussion

### DAY 2 – 2<sup>nd</sup> DECEMBER 2022

#### SESSION 4. NEW THERAPEUTIC STRATEGIES IN UROLOGICAL TUMORS

Chairs: Dr. Ignacio Duran– Hospital Marqués de Valdecilla, Santander | Dr. Joan Montero– IBEC, Barcelona

#### 09:00–09:20 Modelling prostate cancer plasticity through homologous recombination deficiency.

Dr. Alvaro Aytes – Institut Català d'Oncologia – IDIBELL, L'Hospitalet del Llobregat.

#### 09:20–09:40 Dual inhibition of MEK and PI3K $\beta$ / $\delta$ signaling as a novel therapeutic strategy for docetaxel resistant metastatic prostate cancer.

Dr. Vicenç Ruiz de Porras – Institut Català d'Oncologia, Badalona – B-ARGO – IGTP

#### 09:40–10:00 Targeting the intrinsic apoptosis pathway: A window of opportunity for cancer?

Dr. Joan Montero – IBEC, Barcelona.

#### 10:00–10:20 Antibody-drug conjugates in uro-oncology.

Dr. Ignacio Duran – Hospital Marqués de Valdecilla, Santander.

10:20–10:40 Discussion

#### 10:40–11:10 COFFEE BREAK

#### SESSION 5. MOVING TOWARDS PERSONALIZED MEDICINE IN UROLOGICAL TUMORS: WHERE ARE WE NOW AND WHERE ARE WE GOING?

Chairs: Dr. Albert Font Pous – Institut Català d'Oncologia, Badalona | Dr. Vicenç Ruiz de Porras– Institut Català d'Oncologia, Badalona – B-ARGO – IGTP, Badalona

#### 11:10–11:30 Molecular characterization in renal cancer: clinical implications.

Dr. Jesús García-Donas – Centro Oncológico Clara Campal, Madrid.

#### 11:30–11:50 Tumor and gut microbiome as emerging biomarkers in urological cancers.

Dr. Marc Oliva– Institut Català d'Oncologia, L'Hospitalet de Llobregat.

#### 11:50–12:10 Future directions of precision oncology in prostate cancer

Dr. Himisha Beltran – Dana Farber Cancer Institute, Boston, Massachusetts, USA.

#### 12:10–12:30 Cellular immunotherapy against urological tumors

Dr. Manel Juan – Hospital Clínic de Barcelona.

#### 12:30–12:50 Current challenges in the treatment of urothelial cancer

Dr. Joaquim Bellmunt – Dana Farber Medical Center, Boston.

12:50–13:20 Discussion

13:20–13:30 CONCLUSION AND CLOSING REMARKS